Marinus Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings.

 
post partum depression indications

Postpartum Depression

Striving to Support Strong Mother-Baby Bonds

Developing therapies with the potential to address postpartum depression more quickly and in an outpatient setting.

 

Orphan Epilepsies

Aspiring to Give Children Seizure-Free Days

Ganaxolone offers the potential to safely decrease seizure frequency in children with refractory epilepsy.

 

WHY WE WORK

To make a difference in the lives of patients and their families.